Title Center Name Physician

A Multicenter, Open-label, Phase 2 Trial to Assess the Efficacy and Safety of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) in Participants with Advanced Melanoma Previously Exposed to an Anti-PD-1/L1 Agent (LEAP-004)

NCT ID : 03776136
Protocol Number : MK7902-004
Phase : 2

Melanoma, Skin and Soft Tissue Tumors

O'Day

StimRouter™ for Pain Management in Post-stroke Shoulder Pain (PSSP)

NCT ID : 03093935
Protocol Number : STMR – PAIN 002 PSSP

Brain Tumors & Neuroscience

Kesari

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT ID : 03709888
Protocol Number : JWCI-17-0101

Brain Tumors & Neuroscience

Clinical Trials

Kesari

An Exploratory Study of Caregiver Burden Among Family Caregivers of Patients With Cancer

NCT ID : 03069105

Clinical Trials

Saria

CancerLife: Patient-Driven Solution in Cancer Care

NCT ID : 03371147

Clinical Trials

Saria

Allogeneic Human Mesenchymal Stem Cells for Alzheimer’s Disease

NCT ID : 02833792
Protocol Number : STEM105-M-AD
Phase : 2

Brain Tumors & Neuroscience

Kesari

Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial

NCT ID : 02873312
Protocol Number : CP-STMR-OAB-002

Brain Tumors & Neuroscience

Kesari

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

NCT ID : 02847559
Protocol Number : NU 16C02
Phase : 11

Brain Tumors & Neuroscience

Kesari

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

NCT ID : 03425292
Protocol Number : JWCI-17-0801

Brain Tumors & Neuroscience

Kesari

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (STELLAR)

NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : 3

Brain Tumors & Neuroscience

Kesari

TALAPRO-1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men with DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)

NCT ID : NCT03148795
Protocol Number : MDV3800-06 (C3441006)
Phase : 2

Urology and Urologic Oncology

Twardowski

A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer

NCT ID : NCT03860272
Protocol Number : C-800-01
Phase : 1

Melanoma, Skin and Soft Tissue Tumors

O'Day

A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)

NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2

Melanoma, Skin and Soft Tissue Tumors

O'Day

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

NCT ID : 03637764
Protocol Number : ACT15377
Phase : 1 and 2

Brain Tumors & Neuroscience

Kesari

Open- Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer

NCT ID : 03686683
Protocol Number : P17-1 (ProVent)
Phase : 3

Urology and Urologic Oncology

Twardowski

Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2

Melanoma, Skin and Soft Tissue Tumors

O'Day

Using Virtual Reality (VR) Models for Preoperative Planning

NCT ID : 03334344
Protocol Number : VR Models

Urology and Urologic Oncology

Linehan

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I

Brain Tumors & Neuroscience

Kesari

A Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab

NCT ID : 03538314
Protocol Number : UV1-hTERT-MM-103
Phase : I

Melanoma, Skin and Soft Tissue Tumors

O'Day

Phase II Trial of AV-GBM-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) as Adjunctive Therapy Following Primary Surgery plus Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03400917
Protocol Number : CL-GBM-P01-US
Phase : II

Brain Tumors & Neuroscience

Kesari

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

NCT ID : 03480646
Protocol Number : 1205-201
Phase : Ib/II

Urology and Urologic Oncology

Twardowski

The Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With LG NMIBC at Intermediate Risk of Recurrence

NCT ID : 03558503
Protocol Number : TC-BC-12
Phase : 2

Urology and Urologic Oncology

Linehan

A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)

NCT ID : 03131960
Protocol Number : MT-St-03
Phase : 3

Brain Tumors & Neuroscience

Achrol

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3

Melanoma, Skin and Soft Tissue Tumors

O'Day

A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma

NCT ID : 03463265
Protocol Number : GBM-007
Phase : 2

Brain Tumors & Neuroscience

Kesari

Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Urology and Urologic Oncology

Twardowski

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

NCT ID : 03425643
Protocol Number : MK-3475-671
Phase : IIB or IIIA

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

O’Day

Phase 1B, Multicenter, Open-Label Study Of Marizomib Combined with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma

NCT ID : 02903069
Protocol Number : MRZ-112 (20161905)
Phase : Ib

Brain Tumors & Neuroscience

Kesari

A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas

NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II

Brain Tumors & Neuroscience

Kesari

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy

NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II

Urology and Urologic Oncology

Wilson

An Open-Label Non-Randomized, Multicenter Phase 2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults with Glioblastoma at First Recurrence or Progression

NCT ID : 02858895
Protocol Number : MDNA55-05
Phase : II

Brain Tumors & Neuroscience

Achrol

A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer

NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I

Brain Tumors & Neuroscience

Kesari

A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors

NCT ID : 02646748
Protocol Number : INCB39110-107 (20160236)
Phase : Ib

Gynecologic Oncology

Melanoma, Skin and Soft Tissue Tumors

Minimally Invasive Chest Surgery and Thoracic Surgical Oncology

Urology and Urologic Oncology

O'Day

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

NCT ID : NCT03149003
Protocol Number : BBI-DSP7888-201G
Phase : II

Brain Tumors & Neuroscience

Kesari

Recombinant Human Arginase 1 (RhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety And PK/PD

NCT ID : 2285101
Protocol Number : BCT-100-005
Phase : I

Melanoma, Skin and Soft Tissue Tumors

O'Day